- Posted Tuesday January 19, 2016
Barrett-Jackson Cancer Research Fund at TGen established in memory of auction Chairman and CEO Craig Jackson's father and brother
SCOTTSDALE, Ariz. - Jan. 19, 2016 - A powerful racetrack-worthy 2015 Chevrolet Camaro Z/28 will be auctioned at the 45th annual Barrett-Jackson Scottsdale Auction to raise cancer research funds for the Translational Genomics Research Institute (TGen).
This white and black Z/28, with 505 horsepower but fewer than 500 actual miles, was given by an anonymous donor to Barrett-Jackson to support TGen. It is scheduled to cross the auction block about 7:30 p.m. on Jan. 28. The auction runs from Jan. 23-31 at WestWorld of Scottsdale.
Each year on TGen's behalf, Barrett-Jackson helps secure and auction donated rare and classic cars, raising essential dollars for the Barrett-Jackson Cancer Research Fund at TGen, in Memory of Russ and Brian Jackson. The fund, established in 2010, is a salute to auction Chairman and CEO Craig Jackson's father, Russ - one of the founders of Barrett-Jackson - and brother, Brian, whose lives were cut short by colon cancer.
"TGen's cancer research is something very close to me," said Craig Jackson, chairman and CEO of Barrett-Jackson. "I'm honored to help support this invaluable cause and to be able to do so in memory of my father and brother. It's very moving to see the collector car community come together, bid from the heart and make a difference for organizations like TGen."
Total giving for all charitable causes by Barrett-Jackson over the years has topped $84.6 million.
"Craig Jackson's involvement enables TGen's research to help patients around the world," said Michael Bassoff, President of the TGen Foundation. "Craig and his team at Barrett-Jackson have provided the leadership necessary to bring TGen's personalized medicine to the families that need it the most."
The Z/28's 7-liter, 505-horsepower, V8 engine can pull more than 1G and hit 0-60 mph in 4.4 seconds. This model Z/28 has lapped Germany's 12.9-mile Nurburgring - one of the world's most challenging racetracks with an elevation climb of more than 1,000 feet - in 7:38.47 minutes in inclement weather.
Originally introduced in 1967, the Camaro Z/28 was designed specifically to compete in Trans-Am 2 class races. Lightweight, nimble and incredibly powerful, the original Z/28 was built to rule the road-racing circuit. The 2015 Camaro Z/28 track car carries the same racing credentials, incorporating a performance-first design philosophy that takes advantage of state-of-the-art, race-proven technology.
Since 2011, donated rare and classic automobiles sold at auction by Barrett-Jackson, and other gifts, have raised nearly $2 million for TGen cancer research. Cars previously auctioned for TGen have included a 2013 Ford Mustang 2 Door Coupe, a 2008 Shelby GT Barrett-Jackson Edition, and a 1993 Chevrolet Corvette 40th Anniversary coupe.
Craig Jackson also has acted as a national spokesperson for TGen, spreading the word about how the institute's research may lead to improved quality of life for cancer patients.
More than 132,000 Americans will be diagnosed this year with colon or rectal cancer, and nearly 50,000 patients will succumb to these diseases, the second-leading cause of cancer-related death in the U.S.
An additional 220,000 American men this year will be diagnosed with prostate cancer, which this year will kill more than 27,000 patients, the second-leading cause of cancer death among men in the U.S.
For more information, please visit barrett-jackson.com and www.tgen.org.
# # #
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with neurological disorders, cancer, and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit:www.tgen.org. Follow TGen onFacebook,LinkedInandTwitter @TGen.
TGen Senior Science Writer